DIVERSA Technologies
Maria de la Fuente Freire is a cofounder of DIVERSA since May 2021 and serves as the Head of the Nano-Oncology and Translational Therapeutics group at Servizo Galego de Saúde, where research focuses on developing new experimental therapies and diagnostic modalities in translational oncology. Maria has a rich academic background, having held positions such as Research Fellow at the University of Santiago de Compostela and Postdoctoral Researcher at UCL-School of Pharmacy, among others. Maria’s educational credentials include an Executive MBA from Esade and Galicia Business School, a high-level management program from IESE Business School, a PhD in Pharmaceutical Technology with a focus on Nanotechnology and Drug Delivery from Universidad de Santiago de Compostela, and a Licenciatura en Farmacia, specializing in clinical health.
This person is not in any teams
DIVERSA Technologies
Our drug delivery technology based on lipidic nanoemulsions allows for safe and physiological intracellular delivery of complex macromolecules (peptides, proteins and nucleic acids) and small hydrophobic molecules. The platform has broad and fresh IP protection and is fully scalable and regulatory compliant. At DIVERSA, we want to bridge the gap between molecules and patients, between drug discovery and clinical application. We want to create new opportunities to improve patients' quality of life. Despite the discovery of many new targets and therapeutic molecules in labs around the world, less than 3% of them will make it to clinical stages. Most of these new molecules are discarded in the early stages of research, mostly because they cannot access the interior of the cell, where 3 out of 4 new molecules have their targets. We want change that. We want to spearhead the therapeutic revolution.